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Zinc might strengthen our immune 
systems and fortify our bones, but it 
also helps a cancer-causing skin virus 
take hold, according to Lazarczyk 
et al. (page 35).
Most people harbor within 
their skin a human papillomavirus 
(HPV) subtype called HPV EV. 
Although this virus is usually 
harmless, certain infected individ-
uals develop wart-like skin lesions 
that eventually grow into tumors. These rare, susceptible 
individuals have mutated versions of ER membrane pro-
teins known as EVER1 and EVER2.
Lazarczyk et al. now show that normal versions of EVER 
proteins counter the virus by depriving the cell’s nucleus of zinc—
a known transcription booster. Zinc is shuttled into the nucleus 
by a transporter called ZnT-1. But the team found that EVERs 
bound and retained ZnT-1 at the ER, thus keeping the level 
of zinc in the nucleus low.
Cells containing mutated versions of EVERs had abnor-
mally high levels of nuclear zinc, which activated proprolifer-
ation transcription factors, thus increasing the host cell’s ability 
to seed tumors. Adding back functional EVERs reduced cellular 
proliferation. As the extra zinc also activated cellular tran-
scription factors required for viral replication, EVERs might 
normally block viral replication as well.
Unlike HPV EV, the group found, other HPVs fought 
back against EVER proteins. One version that causes gen-
ital cancer, for instance, manufactured a protein that dis-
rupted the EVER–ZnT-1 complex and freed zinc for 
nuclear entry. 
An inflammation-enhancing virus
A dormant virus that is 
awoken by inflammation 
enhances this potentially 
dangerous immune response 
to remain active, say Qiu et al. 
(page 19).
The human cytomegalovirus 
(HCMV) switches off its own 
replication after infection 
to stay off the immune 
system’s radar. Unlike other 
dormant viruses that require 
a weakened immune system 
to reactivate, HCMV thrives 
amidst a roaring immune response. The virus replicates when its 
host cells—monocytes and other inflammation-causing cell types—
proliferate. These cells produce cytokines such as TNF that directly 
stimulate the promoters of some HCMV genes.
Active HCMV infections are thus commonly found within the 
inflamed tissues of patients suffering from chronic inflammatory 
diseases, such as atherosclerosis. But whether the reactivated virus is 
just a lucky beneficiary of local inflammation or actively perpetuates 
inflammation was under debate.
Qui et al. now find that HCMV enhances inflammation by coercing 
nearby noninflammatory cells to join the fray. Smooth muscle cells 
isolated from inflamed tissues harbored active HCMV and produced 
leukotrienes—powerful proinflammatory lipids. Leukotriene production 
had been thought to be restricted to immune cells. How the virus 
reprograms the previously harmless muscle cells to become 
inflammatory is not clear.
The virus’s escalation of inflammation probably amplifies its own 
growth and spread; smooth muscle cells, monocytes, and other 
HCMV host cells migrate when activated and might thereby seed 
new sites of viral activity. 
HCMV induces infected cells to produce 
leukotrienes (pink) that attract more 
inflammatory cells (dark blue).
EVERs keep zinc out of 
the nucleus by trapping 
zinc transporters (green) 
at the ER (red).
New vaccines may 
provide full coverage
On page 117, Giefing et al. report the dis-
covery of two new vaccine candidates that 
might protect humans against all 90 versions of 
a deadly bacterium.
This bacterium, Pneumococcus, invades the 
lungs, blood, and eventually brain to cause 
pneumonia, sepsis, and meningitis, respectively. 
Surface proteins from this bug are currently 
being used as vaccines to induce the body to 
produce protective antibodies. But these vaccines, 
which comprise proteins from only a few types 
of Pneumococcus, are not effective against other 
variants, due to extreme sequence diversity in 
the surface proteins.
Giefing et al. now identify two bacterial 
antigens that are nearly identical among all 
pneumococcal strains and that induce potent 
antibodies in vivo. The authors hunted for con-
served bacterial antigens that would be exposed 
on the pathogen during disease. Antibodies iso-
lated from exposed but healthy humans and 
from those recovering from infection were used 
to identify pneumococcal proteins that were 
targeted by the protective antibody response.
Both of the newly identified antigens in-
duced antibodies that protected immunized 
mice against several other pneumococcal variants. 
The antigens might be potent targets because 
they come from a protein that is essential for 
bacterial growth and survival and thus unlikely 
to mutate. The team is currently testing their 
vaccines in clinical trials. 
Block the zinc, starve the virus